What is the Status of PXT3003 for CMT1A?

As of late 2024, PXT3003 remains an investigational drug, meaning it is not currently approved by the FDA or EMA for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) ^[1][2]. While early studies showed promise, recent significant setbacks in the latest Phase 3 clinical trial (the PREMIER trial) and severe financial difficulties for the developing company, Pharnext, have stalled the drug’s path to approval ^[1][3].

What is PXT3003?

PXT3003 is a low-dose combination of three repurposed medications: baclofen, naltrexone, and sorbitol ^[1][4]. In preclinical models, this specific combination was designed to reduce the overproduction of the PMP22 protein, which is the underlying genetic cause of CMT1A ^[4][5]. Animal studies suggested that the drug could help restore muscle innervation (improve the critical communication connections between nerves and muscles so signals get through effectively) ^[4][5].

Important Safety Note on Off-Label Use: Because PXT3003 is made from existing repurposed medications, some patients wonder if their doctor can prescribe these three drugs together. You should not attempt to combine or compound these medications yourself. PXT3003 relies on a highly specific, low-dose synergistic ratio, and off-label compounding lacks the rigorous clinical monitoring required to ensure safety and effectiveness ^[4][5].

Clinical Trial Journey and Recent Setbacks

The path through clinical trials for PXT3003 has been complicated by both manufacturing and efficacy challenges:

• The PLEO-CMT Trial (First Phase 3): This initial large study showed that patients receiving a high dose of PXT3003 experienced a statistically significant improvement in their neuropathy symptoms, measured by the Overall Neuropathy Limitations Scale (ONLS), a clinical tool used to assess a person’s ability to perform everyday activities using their arms and legs ^[1]. However, an unexpected issue with the drug’s formulation—specifically, the formation of crystals in the high-dose liquid—forced the company to prematurely stop that arm of the trial ^[1]. Because this led to a high rate of missing data, regulatory agencies required another trial to confirm the results ^[1].
• The PREMIER Trial (Second Phase 3): Designed to overcome the previous data issues, this trial evaluated the high-dose formulation in patients over 15 months ^[1]. Unfortunately, the PREMIER trial did not meet its primary endpoint, meaning it failed to prove a statistically significant improvement in the ONLS compared to a placebo ^[1].

Despite these setbacks in demonstrating efficacy, PXT3003 has consistently been shown to be safe and well-tolerated by patients across multiple clinical trials ^[1][6].

Regulatory Hurdles and Company Updates

The failure of the PREMIER trial to meet its primary efficacy endpoint created a major regulatory hurdle, as a successful Phase 3 trial is typically required for a company to file a New Drug Application (NDA) with the FDA or similar agencies globally ^[1].

Following the disappointing PREMIER trial results, Pharnext—the biopharmaceutical company developing PXT3003—faced severe financial challenges. This culminated in the company entering judicial liquidation (bankruptcy proceedings) in mid-2024 ^[3][7]. Consequently, the ongoing development, future regulatory submissions, and potential availability of PXT3003 (including continuation in open-label extension studies like the VALENCE trial) currently depend on whether another company purchases the rights to the drug to continue its development ^[3][7].

What This Means for Patients

For people living with CMT1A, the delay in PXT3003 is incredibly frustrating, as there are still no approved pharmacological treatments available ^[8][3]. If you are currently enrolled in a PXT3003 extension trial (such as VALENCE), it is crucial to stay in close contact with your trial site coordinator for updates regarding the trial’s status.

While the CMT community waits for clarity on PXT3003’s future, standard of care—including physical therapy, orthotics (like AFOs), and exercise—remains the best tool for managing disease progression. All patients are encouraged to remain connected with major advocacy organizations (such as the Charcot-Marie-Tooth Association or the Hereditary Neuropathy Foundation) for the latest news on whether a new sponsor will take over PXT3003, as well as updates on other emerging therapies (such as early gene therapy research) currently in the pipeline.